Last reviewed · How we verify
SARS-CoV-2 Virus 1x10^3 TCID50
SARS-CoV-2 Virus 1x10^3 TCID50 is a Biologic drug developed by Imperial College London. It is currently in Phase 1 development.
At a glance
| Generic name | SARS-CoV-2 Virus 1x10^3 TCID50 |
|---|---|
| Sponsor | Imperial College London |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 Virus 1x10^3 TCID50 CI brief — competitive landscape report
- SARS-CoV-2 Virus 1x10^3 TCID50 updates RSS · CI watch RSS
- Imperial College London portfolio CI
Frequently asked questions about SARS-CoV-2 Virus 1x10^3 TCID50
What is SARS-CoV-2 Virus 1x10^3 TCID50?
SARS-CoV-2 Virus 1x10^3 TCID50 is a Biologic drug developed by Imperial College London.
Who makes SARS-CoV-2 Virus 1x10^3 TCID50?
SARS-CoV-2 Virus 1x10^3 TCID50 is developed by Imperial College London (see full Imperial College London pipeline at /company/imperial-college-london).
What development phase is SARS-CoV-2 Virus 1x10^3 TCID50 in?
SARS-CoV-2 Virus 1x10^3 TCID50 is in Phase 1.